NCT03443063View on ClinicalTrials.gov

Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 7, 2018

Primary Completion Date

August 24, 2018

Study Completion Date

August 24, 2018

Conditions

Renal Impairment

Interventions

DRUG

Lemborexant

oral tablet

Trial Locations (2)

32809

Orlando Clinical Research Center, Orlando

33014

Clinical Pharmacology of Miami, LLC, Miami

All Listed Sponsors

collaborator

Purdue Pharma LP

INDUSTRY

lead

Eisai Inc.

INDUSTRY

NCT03443063 - Study to Evaluate the Pharmacokinetics of Lemborexant (E2006) and Its Metabolites in Subjects With Normal Renal Function or With Severe Renal Impairment | Biotech Hunter | Biotech Hunter